Risk of injection site reactions and local irritation in the blood vessels, tissues and organs or delay in therapy.
FDA recommends a decreased starting dose for both women and men.
Injected particulate matter may result in local inflammation, phlebitis, and/or low level allergic response.
Study finds lower risk of clot-related strokes, bleeding in brain, and death for Pradaxia versus warfarin, but increased risk of major GI bleeding.
Failure could result in the balloon pump shutting down without warning, which could result in worsened heart failure, decreased blood flow to the heart, and/or decreased blood flow to the body and brain.
Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients.
L'Agenzia Europea dei Medicinali ha avviato una revisione dei medicinali contenenti idrossizina.
L’Agenzia Italiana del Farmaco, in accordo con l’Agenzia Europea dei
Medicinali, rende disponibili nuove ed importantii nformazioni sul ritiro dal commercio del medicinale Crixivan 400 mg capsule rigide a base di Indinavir.
80.211.154.110
